

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following Grade ≥ 3 adverse events was most frequently reported with ifinatamab deruxtecan among patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) in the Phase II IDEate-Lung01 study?
 - a. Gastrointestinal adverse events
 - b. Hematologic adverse events**
 - c. Interstitial lung disease/pneumonitis

2. Ifinatamab deruxtecan has been granted priority review by the FDA for treatment in which of the following settings?
 - a. For heavily pretreated ES-SCLC in patients with no satisfactory alternative options
 - b. For previously treated ES-SCLC after 1 prior line of systemic treatment including platinum-based chemotherapy**
 - c. In combination with atezolizumab and platinum/etoposide as first-line therapy for newly diagnosed ES-SCLC
 - d. In combination with durvalumab after chemoradiation therapy for limited-stage SCLC (LS-SCLC)

3. Which of the following drug types best describes the pharmacologic class of alisertib?
 - a. DLL3-targeted T-cell engager
 - b. Small-molecule aurora kinase inhibitor**
 - c. B7-H3-targeted antibody-drug conjugate

4. What is the target of the T-cell engager gocatamig?
 - a. B7-H3
 - b. DLL3**
 - c. SEZ6
 - d. TROP2

5. The Phase III ADRIATIC study evaluating durvalumab versus placebo for patients with LS-SCLC and no disease progression after concurrent chemoradiation therapy reported which of the following efficacy outcomes at the first planned interim analysis?
 - a. Inferior overall survival (OS) and progression-free survival (PFS)
 - b. A significant improvement in PFS but not OS
 - c. A significant improvement in PFS and OS**